drugset / Trial / NCT01438814
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI) side effects in treatment naive patients of with type 2 diabetes mellitus.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 5 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
| Subject | Metformin | Small molecule | 2000 mg | — |